Gliomas are the most frequent primary tumors of the brain, and for highly malignant gliomas there is no successful treatment. The tumor microenvironment contains large numbers of infiltrating microglia and macrophages (MM). There is increasing evidence that the tumor-associated MM support glioma expansion. CD38 is a multifunctional ectoenzyme that uses nicotinamide adenine dinucleotide as a substrate to generate second messengers. Previously we showed that CD38 deficiency modulates microglial "activation" and impaired recovery from head trauma by a microgliaassociated mechanism. In view of the supportive role of MM in glioma progression and the role of CD38 in microglia activation, we hypothesize that deficiency of CD38 in the tumor microenvironment would inhibit glioma progression. Using the syngeneic GL261 model of glioma progression in wild-type and CD38 null mice, we show here that CD38 deficiency significantly attenuates glioma expansion and prolongs the life span of the glioma-bearing mice. The CD38 deficiency effect was associated with increased cell death and decreased metalloproteinase-12 expression in the tumor mass, as well as modulation of the tumor-induced MM properties, as indicated by a reduction in the expression of the MM marker F4/80 and matrix metalloproteinases. Our results thus suggest that CD38 participates in the tumor-supporting action of MM and that targeting CD38 might be a potential therapeutic approach for glioma treatment.
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Keywords: brain, cancer, CD38, glioma, microglia. G liomas are the most common primary tumors of the brain. Despite aggressive treatment, the prognosis of highly malignant gliomas is poor. Increasing evidence suggests that glioma progression is regulated by the tumor microenvironment. Microglia/ macrophages (MM) are the major microenvironmental cells in the tumor, constituting up to 40% of the tumor mass. 1 Microglia are the resident immune, myeloidoriginated cells of the CNS. In a healthy CNS, microglia survey the brain's environment for damage or perturbation of homeostasis. Once they sense such a condition, they respond by acquiring various features, collectively termed activation. Activated microglia have been suggested to play both beneficial and harmful roles in various brain pathologies, including neurodegenerative diseases and acute injuries. 2 In pathological conditions, macrophages infiltrate the brain and act together with the resident microglia. Since it is difficult to distinguish between microglia and macrophages, we refer to these cells in pathological conditions as MM.
Although the tumor-associated (T)MM may act as tumor suppressors by secreting free radicals and by recruiting cells of the adaptive immune system, compelling evidence demonstrates that they promote glioma progression and metastasis (for review, see Badie and Schartner, 1 Watters, Schartner, and Badie, 3 and Yang et al. 4 ). TMM are attracted toward glioma in large numbers, and the TMM density in gliomas positively correlates with tumor grade. TMM can release many factors, including extracellular matrix proteases and cytokines, which may directly or indirectly influence tumor invasiveness and proliferation. 1 Furthermore, depletion of microglia from organotypic brain slices 5 or TMM from the tumor area in vivo 6 largely impedes glioma expansion. Thus, abrogating the tumor-supporting effect of TMM may provide a new therapeutic approach to treat glioma. This may be achieved by targeting molecules known to modulate microglia responses to activation signals. Previously, we 7, 8 and others 9 demonstrated that CD38 regulates microglial activation. A role of CD38 in microglial function was also shown in vivo in a head trauma model where CD38 deficiency reduced the accumulation of activated MM in the injured brain area and worsened the recovery of the mice from the trauma.
10
CD38 is a nicotinamide adenine dinucleotide (NAD) glycohydrolase and ADP-ribosyl cyclase. It is expressed by various cell types, including myeloid-derived cells. The extracellular enzymatic domain of CD38 uses NAD+ and NADP+ to catalyze the formation of the calcium-mobilizing metabolites adenosine diphosphate ribose (ADPR), cyclic ADPR, and nicotinic acid adenine dinucleotide phosphate. Notably, CD38 may also act as a cell-surface receptor.
11 CD38 can play a role in several biological systems, as indicated by studies using CD38-deficient mice. Accordingly, CD38 deficiency may impair both innate and adaptive immune responses. These include impaired neutrophile, monocyte, and dendritic cell trafficking and impaired T cell priming, as well as reduced humoral responses and enhanced susceptibility to infection. 12, 13 Additional effects associated with CD38 deficiency include attenuation of airway hyperreactivity 14 and impairments of insulin secretion, 15 osteoclast-mediated bone resorption, 16 and oxytocin secretion. 17 In cells of the immune system, levels of CD38 expression may vary as functions of the activation state, in a manner that is cell-type dependent. In T cells and in cells of the myeloid lineage, for example, the levels of expression increase upon activation. 18 The expression of CD38 is also relevant in neoplastic cells. Specifically, in chronic lymphocytic leukemia, a high percentage of CD38-expressing leukemic cells is associated with unfavorable prognosis, as well as with cell activation and proliferation. 19 In view of our previous results that CD38 regulates microglial activation, we reasoned that targeting CD38 in the tumor microenvironment may attenuate glioma progression. To test this hypothesis, glioma expansion was examined in wild-type (WT) or Cd38 2/2 C57BL/ 6 mice intracranially injected with the syngeneic glioma GL261 cells. Our results show that CD38 deficiency delayed glioma progression, ie reduced tumor volume and moderately prolonged survival duration of tumor-bearing mice. The reduction in the tumor volume was associated with enhanced cell death in the tumor mass as well as modulation of TMM features.
Materials and Methods

Reagents
Reagents used were purchased from Sigma, unless indicated otherwise.
Antibodies
The following primary antibodies were used: rabbit antiionized calcium-binding adaptor molecule 1 (Iba1) polyclonal antibody (Ab; 
Cell Culture
The GL261 glioma cells were provided by Professor Geza Safrany (Department of Molecular and Tumor Radiobiology, Budapest, Hungary) and were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL), supplemented with 10% fetal calf serum (FCS), 1% penicillin-streptomycin, and 4 mM L-glutamine and grown at 378C with 5% CO 2 . Green fluorescent protein (GFP) -expressing GL261 (GFP-GL261) was generated by infection of GL261 cells with the pHR ′ cytomegalovirus GFP virus. 22 GFP-expressing cells were isolated by a FACSAria fluorescence-activated cell sorter (Becton Dickinson).
Intracranial Injection of GL261 Glioma Cells and MRI
Four-month-old male WT and Cd38 2/2 C57BL/6 mice were anesthetized by an i.p. injection of ketamine (100 mg/kg) and xylazine (20 mg/kg) and placed in a Kopf Stereotaxic Alignment System. An approximately 1-cm-long cut was made in the scalp, and the skull was exposed. Then, a 2-mm burr hole was drilled 1 mm posterior to the bregma and 1.5 mm lateral to it. Using a Hamilton 10-mL syringe and a 31-g Hamilton needle, we injected 5 × 10 3 or 1 × 10 5 GL261 or GFP-GL261 cells in 3 mL DMEM 3 mm below the cortical surface, at a rate of 1 mL/min. In order to avoid backflow, the needle was left for an additional 1 min before being gradually removed. The scalp was stitched and the mice were allowed to recover in their cages.
Magnetic Resonance Imaging
Following injection, at days 17 and 21 (when 5 × 10 3 GL261 cells were injected) or at days 10, 14, and 17 (when 1 × 10 5 GL261 cells were injected), tumor progression was assessed by gadolinium (Gd)-diethylenetriamine pentacetate (DTPA)-enhanced T1-weighted MRI (Bruker, Biospin). The MRI scans were performed under inhalational 1% -2% isoflurane (Nicholas Piramal) anesthesia in 98% oxygen. Immediately before scan, mice were i.p. injected with 150 mL of 0.1-M Gd-DTPA (Soreq Radiopharmaceuticals). Mice were scanned in a 7T/30 spectrometer (Bruker, Biospin) using a quadrature head coil and a 400-mT/m gradient system. The MRI protocol included Gd-DTPA-enhanced T1-weighted MRI (repetition time ¼ 800 ms and echo time ¼ 12 ms). The field of view was 2 × 2 cm with matrix dimensions of 256 × 128 pixels (reconstructed to 256 × 256). Fourteen slices 0.8 mm thick and with no gap were acquired in coronal orientation. The final image resolution was 0.078 × 0.078 × 1 mm 3 . The tumor area was determined using Medical Image Analysis v.2.4 in MatLab.
Survival Analysis
Following injection of the GL261 cells, mice were monitored and weighed daily. The endpoint was defined by a lack of physical activity and more than 15% reduction in body weight. The probability of survival was calculated using the Kaplan-Meier method, and statistical analysis was performed using a log-rank test.
BrdU Injection
Twenty days after injection of GFP-GL261 cells, BrdU was i.p. injected into the mice (50 mg/kg). Two hours later, the mice were killed and their brains were processed for immunostaining.
Immunoblot Analysis
Twenty-nine days following injection of GL261 cells, mice that reached the death criteria for survival analysis were overdosed with ketamine/xylazine and subsequently perfused. Brains were removed, and the tumorbearing hemisphere was homogenized and lysed for protein extraction. Alternatively protein extracts were prepared from isolated TMM. Thirty to one hundred micrograms of protein from the different samples were separated by 10% or 12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis and electroblotted onto supported nitrocellulose. Each blot was blocked for 1 h in Tris-buffered saline/Tween-20 (10 mM Tris base, 150 mM NaCl, 0.05% Tween-20) containing 5% fat-free milk and then incubated overnight at 48C with a primary Ab (anti -MMP-12, 1:1000; antitubulin, 1:2500; anti-GAPDH, 1:1000). After washing the membranes 3 times (10 min each) with Tris-buffered saline/Tween-20, we incubated the samples for 1 h at room temperature with the appropriate second Ab (goat anti-mouse or goat anti-rabbit IgG peroxidase conjugate, Jackson ImmunoResearch Laboratories). Blots were developed using the Supersignal West Pico Chemiluminescent Substrate kit (Pierce Biotechnology). Each blot was reprobed with anti-tubulin mAb or anti-GAPDH to verify that proteins were uniformly loaded across the gel. The signal, normalized to tubulin or GAPDH, was quantified by the use of EZQuant-Gel software.
Immunostaining
Twenty days following injection of GL261 cells, mice were overdosed with ketamine/xylazine and subsequently perfused and fixed as described. 10 Frozen coronal sections (30 mm) were then cut on a sliding microtome. For pathological analysis of the mitotic cells and for terminal deoxynucleotidyl transferase (2'-deoxyuridine 5'-triphosphate) nick end labeling TUNEL staining, brains were embedded in paraffin and cut into 6-mm sections.
The free-floating sections 23 were immunostained as described previously, 10 
Image Analysis
The peroxidase-immunostained sections were viewed and photographed with a Nikon Plan ×4/0.1NA, Nikon Plan ×10/0.25NA, or Nikon Plan ×40/ 0.65NA objective and a Nikon DS-5M camera. Two to four slices covering representative areas of the entire tumor were captured. The tumor area was captured frame by frame in a ×4 magnification (for BrdU, F4/ 80, and Iba1 staining) (124 images per slice) or ×10 magnification (for CD31, TUNEL, and MMP-12 staining). For GFAP staining, every fourth frame in the tumor boundaries was captured in a ×40 magnification. The density of immunohistochemical staining was determined with the aid of Image-Pro Plus v.5.1 (Media Cybernetics) by expressing the amount of staining as a percentage of the area analyzed.
For analysis of mitotic cells, hematoxylin and eosinstained 6-mm paraffin sections were examined. Two to four slices covering representative areas of the entire tumor were captured. In each slice, the number of mitotic cells was counted in 3 fields.
Isolation of MM
MM from adult mice were isolated as previously described, 24, 25 with minor modifications. Briefly, mice were deeply anesthetized and then subjected to perfusion through the left ventricle with 10 mL of ice-cold sterile saline. Brains were then removed and the injected (right) hemispheres were processed as following. Three hemispheres were pooled and mechanically and enzymatically digested in 10 mL of digestion buffer (0.05% 
/Mg
2+ -free HBSS containing 2 mM EDTA and 20 mM HEPES. The digested brain pieces were triturated and passed through a 100-mM cell strainer. Cells were centrifuged and resuspended in HBSS containing 30% isotonic Percoll and 40 mg/mL DNAse I, passed through a 70-mm cell strainer, and centrifuged at 1000 × g at 48C for 25 min, and debris was removed. For isolation of MM, the cells were transferred to a new tube containing 20 mL of Ca 2+ /Mg 2+ -free phosphate buffered saline (PBS), 0.5% endotoxin and protease-free bovine serum albumin (BSA), and 2 mM EDTA. The cells were then incubated with CD11b-coated anti-mouse microbeads and passed through a magnetic cell separation column (Miltenyi Biotec) according to the manufacturer's instructions.
The isolated CD11b
+ cells (ie, MM) were then either lysed in TRIzol (Invitrogen Life Science) for RNA preparation for quantitative reverse transcription (qRT-)PCR according to the manufacturer's instructions or lysed for preparation of protein extracts. Each CD11b + cell preparation was analyzed for purity by flow cytometry. Approximately 90% of the cells isolated by this procedure were identified as MM (CD11b + /CD45) by use of the PE-conjugated CD11b and FITC-conjugated CD45 Abs (data not shown).
Isolation of Brain Cells for Flow Cytometry
The brains were processed as described for isolation of MM. Following the Percoll gradient step, cells were centrifuged (700 × g, 10 min, 48C), and the resulting cell pellet was incubated (30 min, 48C) in flow cytometry buffer (PBS supplemented with 1% BSA and 0.05% sodium azide) containing the appropriate fluorescenceconjugated Abs or their isotype-matched controls. After incubation, the cells were washed with the flow cytometry buffer. Antigen expression on 1 × 10 4 live cells was determined using a Becton Dickinson FACSort and analyzed using CellQuest and FlowJo 5.7.2 software.
qRT-PCR Analysis
Following total RNA isolation from the isolated MM, cDNA was synthesized using 0.5 mg total MM RNA as a template and random decamer primers in a 20-mL reaction volume using the SuperScript First-Strand Synthesis System (Invitrogen) according to the manufacturer's instructions. The cDNA (10 ng) obtained was used as a template for qRT-PCR using the ABsolute Blue SYBR Green PCR mix (ABgene) and appropriate primers (Supplementary material, Table S1 ; primer concentrations were optimized for each primer set) by the ABI 7300 Real-Time PCR System (Applied Biosystems). The following 3-stage program was employed as instructed by the manufacturer: 2 min at 508C, 15 min at 958C, then 40 cycles of 15 s at 958C and 1 min at 608C. Melting-curve analysis was used to assess primer specificity and product quality by stepwise denaturation of the PCR product. Relative levels of the different transcripts were quantified using the 2 2DDCT method. 26, 27 For the analysis of MMP mRNA levels in the TMM, data were classified into 2 groups: one corresponding to TMM isolated from middle-phase/-size tumors (based on the time post-injection or the tumor volume in MRI) and the second corresponding to large-phase/-size tumors.
Statistical Analysis
Data are presented as the mean + SEM. A 2-way analysis of variance (ANOVA) was used to compare tumor volume (repeated measures) and MMP mRNA expression in TMM. The survival duration of the mice was analyzed by Kaplan-Meier survival analysis followed by a Levy et 
Results
CD38 Deficiency Reduces Glioma Expansion and Extends the Life Span of Glioma-Bearing Mice
To assess the role of CD38 in the tumor microenvironment on glioma progression, we employed the syngeneic model of implantation of GL261 glioma cells into brains of WT and CD38-deficient mice. This model was used because it represents tumor characteristics similar to human glioblastoma multiforme. 29, 30 We injected 5 × 10 3 GL261 cells into the brains of WT and Cd38
2/2
mice, and tumor volume was assessed by Gd-DTPAenhanced T1-weighted MRI analysis at 17 and 21 days post-injection. As shown in Fig. 1A and 1B, the tumor growth in the Cd38 2/2 mice was significantly attenuated, and at 21 days post-injection it was 62% (P ¼ .00001) smaller than in WT mice. Assessment of the survival of the glioma-bearing mice (Fig. 1C) revealed that Cd38 2/2 glioma -bearing mice survived significantly longer than WT-glioma -bearing mice (median survival of Cd38 2/2 mice was 30.5 vs 27 days in WT, P ¼ .0003). The effect of CD38 deficiency on glioma was also examined under more aggressive conditions (injection of 1 × 10 5 cells), in which the tumor expanded faster (due to higher amount of injected glioma cells). As shown in Fig. 1D -F , also under this condition, CD38 deficiency significantly attenuated tumor growth (38% [P ¼ .002], 17 days post-injection) and prolonged survival (Fig. 1G) In view of these results, we next characterized and compared the glioma microenvironment of WT and Cd38 2/2 mice in an attempt to identify the cells in the glioma microenvironment that might account for the CD38 effect on glioma progression. To this end we compared the presence and features of cells known to be present in the tumor microenvironment and/or its vicinity between WT and Cd38 2/2 mice. First we tested whether the accumulation of astrocytes in the tumors was affected by host expression of CD38. Brain sections of glioma-bearing mice were stained with anti-GFAP Abs. As shown in Fig. 2A , the astrocytes were largely excluded from the tumor mass but were highly enriched in the tumor border in both Cd38 genotypes. The potential contribution of astrocytes to the CD38 effect was assessed by determining the density of GFAP staining in the tumor border. Figure 2B shows that the density of astrocytes in the tumor border was similar in both Cd38 genotypes. Together, these results suggest that reactive astrocytes are not involved in the effect of CD38 in the tumor microenvironment on glioma progression.
Next, we examined the role of T cells in the CD38 effect on glioma progression by assessing the levels of (Fig. 3A) . Similarly, no significant difference was observed in the percentage of CD4 + T cells (Fig. 3B) . However, the percentage of CD8 + T cells was lower in the Cd38 2/2 mice compared with WT mice. The similar accumulation of astrocytes and T cells and the reduction in the percentage of cytotoxic T cells imply that the CD38 deficiency effect is not mediated, at least directly, by these cells.
To assess the role of TMM in the CD38 effect on glioma progression, brain sections obtained from glioma-bearing mice were stained with anti-Iba1 (a marker for MM) Abs. Figure 4A shows that the tumor mass was massively populated by Iba1-positive cells, in particular in its borders. In addition, Iba1 staining was observed, although to a lesser extent, all over the brain. Staining with F4/80 Ab also revealed a massive accumulation of MM in the tumor; however, in contrast to Iba1, the F4/80-positive subpopulation was almost exclusively confined to the tumor mass (Fig. 4B) . Assessment of the amount of MM (Iba1-positive cells) in the tumor area revealed that the density of Iba1-positive cells in the tumor area was similar in both Cd38 genotypes (Fig. 4C) . Similarly, no significant difference was observed when the percentage of CD11b-positive cells (marker for MM) of the total immune cell population (CD45-positive cells) in the tumor-bearing hemisphere was determined by flow cytometry (Fig. 4D) . However, examination of the density of F4/80-positive cells revealed that it was significantly lower (30%) in the tumor area in Cd38 2/2 mice compared with WT mice (Fig. 4E) . These results suggest that CD38 deficiency does not affect the amount of MM in the tumor mass but rather may alter their properties. Furthermore, the results also suggest that the CD38-deficiency -mediated changes in the TMM properties may play a role in the inhibition of glioma progression in Cd38 2/2 mice. To further explore whether CD38 can directly affect the TMM, we examined whether these cells express CD38 and the effect of the tumor on such expression. CD38 expression was determined by flow cytometry in CD11b-positive cells obtained from the glioma-bearing hemisphere or control sham-injected hemisphere of WT mice. As shown in Fig. 4F , TMM express membrane CD38. Notably, the expression level of CD38 in the TMM was moderately (25%) but significantly higher than that of the control MM.
CD38 Deficiency Enhances Cell Death and Reduces MMP-12 Expression
Next, we investigated how CD38 deficiency in the tumor microenvironment can attenuate glioma progression. We first assessed cell proliferation and cell death in the tumor. To determine cell proliferation, we counted mitotic cells in the tumor area ( Fig. 5A and B) or measured the density of BrdU staining in the tumor area ( Fig. 5C and D) . No significant difference was observed between WT and Cd38 2/2 glioma-bearing mice in either the number of mitotic cells or in the density of BrdU stained cells in the tumor area. These results suggest that the proliferation rate of the tumor cells in WT and Cd38 2/2 mice is similar and thus that the difference in the tumor size between the 2 genotypes does not seem to result from an effect of CD38 deficiency on cell proliferation. However, analysis of the amount of cell death in the tumor area by the TUNEL assay, which detects dead cells exhibiting fragmented DNA, revealed that the density of TUNEL-stained cells in the tumor area at day 20 was 50% higher in Cd38 2/2 than in WT mice ( Fig. 5E and F) . Since the survival of tumor cells depends inter alia on neovascularization in the tumor, 31 we examined whether the enhanced cell death observed in CD38 deficient mice is due to insufficient vascularization. To this end we assessed the amount of blood vessels in the tumor area by CD31 staining (a marker for endothelial cells). As shown in Fig. 5G and H, no significant difference was observed in the density of CD31 staining in the tumor area between WT and Cd38 2/2 glioma -bearing mice. These results thus suggest that vascularization in the tumor area is not affected by CD38 expression and thus that the enhanced cell death in the tumors of Cd38 2/2 glioma -bearing mice is mediated by other means.
Among the mechanisms that control glioma expansion is invasiveness, which is regulated inter alia by MMPs. 32 Because MMP-12 plays an important role in glioma invasion, 33 we examined whether MMP-12 expression in the tumor mass would be affected by CD38 deficiency. Brain sections obtained from glioma-bearing WT and Cd38 2/2 mice were stained with anti -MMP-12 Abs. As shown in Fig. 6A , in both Cd38 genotypes there is a confined MMP-12 staining in the tumor mass that seems to be localized both intracellularly and extracellularly, as would be expected from a secreted protein such as MMP-12. 34 Assessment of the MMP-12 staining density in the tumor area revealed a modest (25%) but significant (P ¼ .05) reduction in the staining density in the Cd38 2/2 mice compared with WT mice (Fig. 6B) . These results suggest that CD38 deficiency leads to a reduction in MMP-12 levels in the tumor mass. To further substantiate this finding, MMP-12 levels were examined also by immunoblot analysis. Total protein extracts were prepared from tumorbearing brain hemispheres and analyzed for MMP-12 expression. As shown in Fig. 6C , the 45-kDa active form of MMP-12 was detected in the WT and the Cd38 2/2 samples, whereas the proform of MMP-12 (55 kDa) was barely detected (not shown). Quantization of the amount of active MMP-12 in the different samples revealed that it was significantly (P ¼ .039) lower (65%) in the Cd38 2/2 samples than in the WT samples. Taken together, these and the staining results suggest that CD38 deficiency reduces the amount of MMP-12 in the tumor mass. Among the cells that produce MMPs (including MMP-12) are MM 6 ; therefore, we next examined whether CD38 deficiency may regulate glioma-induced expression of MMP-12 as well as other MMPs in TMM. We isolated MM or TMM (CD11b-positive cells) from sham-or tumor-injected brain hemispheres from WT or Cd38 2/2 mice, extracted their total RNA, and determined the mRNA levels of MMP-9, MMP-12, MMP-13, MMP-14, and MMP-19 by qRT-PCR. The analysis revealed that the tumor substantially induced the expression of MMP-14 and MMP-19 mRNAs in the TMM compared with MM isolated from sham-injected brains; however, no significant difference was observed in their mRNA levels in WT and Cd38
2/2
TMM (data not shown). MMP-12 and MMP-13 mRNA levels were also substantially higher in TMM compared with control MM; however, their mRNA levels were significantly lower (2-way ANOVA, P ¼ .01 and P ¼ .014, respectively) in Cd38 2/2 TMM compared with WT TMM (Fig. 7) . Analysis of MMP-12 levels in protein extracts prepared from WT or Cd38 2/2 TMM (CD11b-positive cells) by immunoblotting revealed a trend toward a lower expression (28%) of active MMP-12 (45 kDa) in Cd38 2/2 TMM compared with WT TMM, but this effect was not significant (P ¼ .06).
Discussion
The aim of the present study was to assess the role of CD38 in the tumor microenvironment on glioma progression. The results presented here show that CD38 deficiency delays glioma progression. Accordingly, CD38 deficiency substantially attenuated tumor growth and modestly but significantly prolonged the life span of glioma-bearing mice, suggesting that CD38 in the microenvironment plays a role in tumor progression.
The mechanism whereby CD38 deficiency affects glioma progression may involve, at least in part, alteration in the tumor-supporting activity of the TMM. This is supported by the observation that CD38 is expressed in TMM and that CD38 expression is higher in TMM than in MM. Furthermore, the results also show that CD38 deficiency does not affect the accumulation of TMM in the tumor but rather their features. The latter is suggested by the reduction not only in the density of F4/80 staining in the tumor area but also in the glioma-stimulated mRNA expression of MMP-12 and MMP-13. Importantly, it was shown previously that these MMPs regulate glioma invasion. 33, 35 Notably, our findings also show that the amount of tumor-associated MMP-12 staining and expression of the 45-kDa active form was lower in glioma-bearing Cd38 2/2 mice compared with WT-glioma -bearing WT TMM, as would be expected from the mRNA analysis. However, owing to the TMM isolation procedure, we most likely measure only a subpopulation of this secreted protein, ie, the cellular MMP-12. In addition to MMP-12 and MMP-13, other MMPs such as MT1-MMP (MMP-14) 6 were shown to play an important role in the effect of TMM on glioma expansion. Our results, however, did not reveal an effect of CD38 on the glioma-induced mRNA expression of MMP-14. The notion that at least some of the CD38 deficiency effects on glioma progression are mediated via modulation of the glioma-supporting role of the TMM is further supported by the lack of CD38-dependent changes in the amount of astrocytes and T cells in the tumor area. However, we cannot exclude the possibility that other cells play a role in the CD38-deficiency effect on glioma progression or that CD38 deficiency affects the functionality, but not the amount, of microenvironment cells. Further studies are needed to assess this possibility. Our finding that CD38 deficiency enhances cell death and reduces MMP expression (at least MMP-12) in the tumor mass suggests that the effect of CD38 deficiency on the tumor is multifunctional and may involve various pathways such as cell death and invasiveness. How CD38 deficiency in the tumor microenvironment enhances cell death is not known. A possible mechanism could be via lack of sufficient vascularization. This, however, does not seem to be the case because we did not observe differences in the densities of CD31 staining in the tumor area between WT and Cd38 2/2 mice. In addition, we did not observe CD38-dependent differences in expression of apoptotic proteins (eg, active caspase-3, Bax, Bak, and Bcl-x L ) (data not shown) in protein extracts prepared from the tumor-bearing hemisphere. Thus CD38 deficiency in the glioma microenvironment does not alter the expression of at least these important components of the apoptotic machinery. Other tumor microenvironment-associated agents that may contribute to the enhanced cell death effect may be lack of survival factors and/or cytotoxic molecules such as NO. Further studies are needed to assess these possibilities.
CD38 is one of the major NADases in mammalian tissues; thus CD38 deficiency may lead to enhancement in NAD levels in tissues 36 of Cd38 2/2 mice and the tumor microenvironment. It was shown previously that NAD can exert toxic effects in some systems. 37, 38 Thus CD38 deficiency might regulate glioma progression by promoting NAD-induced glioma cell death. Although we cannot exclude this possibility, we do not favor it because treatment of GL261 cells in vitro with 1 or 10 mM NAD for 48 h did not affect the viability of the cells (data not shown).
We show here that CD38 deficiency in the glioma microenvironment attenuates glioma expansion. This result also supports the notion that the glioma microenvironment, probably by the action of (but not necessarily exclusively) TMM, supports glioma progression. 39 In view of the ineffectiveness of the current anti-glioma treatments, which are aimed largely against the tumor cells, an alternative approach based on targeting the supporting microenvironment might have a therapeutic benefit. Our results suggest that CD38 might be such a target. Although the effect of CD38 depletion by itself is not curative, it is feasible that a combination of targeting CD38 (in the tumor microenvironment) and the glioma tumor cells will have a synergistic impact on glioma progression and be used in the future as a potential therapeutic approach for glioma therapy. . Expression levels were significantly lower in Cd38 2/2 mice compared with WT (*P ¼ .039, Student's t test) (n ¼ 9 WT and 4 Cd38 2/2 mice).
